Obsidian Therapeutics moved to combine with Galera Therapeutics in a merger that brings $350 million in funding earmarked for cancer drug trials. The transaction is positioned around Obsidian’s tumor-infiltrating lymphocyte (TIL) cell therapy strategy and its stated aim to demonstrate advantages over Iovance Biotherapeutics’ marketed TIL approach in melanoma. The report says the deal structure would provide a public listing for the combined company plus a private placement to support clinical development across the pipeline. For the field, the move underscores continued investor appetite for cellular therapy platforms while trials become more differentiating on manufacturing and clinical outcomes. Obsidian’s positioning against an established competitor signals that the next competitive phase in TIL may depend on incremental efficacy, logistics, and trial design rather than only “category-level” promise.